One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie
One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, today announced support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care.
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples
One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™.
One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies
One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced financial support via a Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop the first single-cell assay for antibody-drug conjugates (ADC) therapies in oncology.
Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology
Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single nuclei transcriptomic analysis into the patient care pathway.
One Biosciences’ Single Cell Data Mining Algorithm “MAYA” Featured in Nature Communications
One Biosciences, a biotech leveraging the power of single-cell analysis and AI to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions, today announced that its single-cell data mining algorithm named “MAYA” article was published in the March edition of Nature Communications journal.
One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program
One Biosciences, a biotech company co-founded by Dr. Céline Vallot, Institut Curie and Home Biosciences, combining the power of AI and single-cell technologies to discover new therapeutic targets and develop novel precision medicines, announced today that it initiated the LARYCARE prospective clinical study for single-cell profiling of larynx and hypopharynx carcinoma.
